{"nctId":"NCT02020369","briefTitle":"Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors","startDateStruct":{"date":"2014-04"},"conditions":["Hemophilia A With Inhibitors","Hemophilia B With Inhibitors"],"count":27,"armGroups":[{"label":"FVIIa: 75 µg/kg first, then 225 µg/kg","type":"EXPERIMENTAL","interventionNames":["Biological: Coagulation Factor VIIa (Recombinant)"]},{"label":"FVIIa: 225 µg/kg first, then 75 µg/kg","type":"EXPERIMENTAL","interventionNames":["Biological: Coagulation Factor VIIa (Recombinant)"]}],"interventions":[{"name":"Coagulation Factor VIIa (Recombinant)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* be male with a diagnosis of congenital hemophilia A and/or B of any severity\n* have one of the following:\n* a positive inhibitor test Bethesda Unit (BU) ≥ 5 (as confirmed at screening by the institutional lab), OR\n* a BU\\<5 but expected to have a high anamnestic response to FVIII or FIX, as demonstrated from the subject's medical history, precluding the use of Factor VIII or IX products to treat bleedings, OR\n* a BU\\<5 but expected to be refractory to increased dosing of FVIII or FIX, as demonstrated from the subject's medical history, precluding the use of Factor VIII or IX products to treat bleedings\n* be 12 years or older, up to and including 75 years of age (NOTE: different age restrictions may apply per local regulation and/or ethical considerations)\n* have at least 3 bleeding episodes of any severity in the past 6 months be capable of understanding and willing to comply with the conditions of the protocol\n* have read, understood and provided written informed consent (patient and/or parent(s)/legal guardian(s) if \\<18 years of age)\n\nExclusion Criteria:\n\n* have any coagulation disorder other than hemophilia A or B\n* be immuno-suppressed (i.e., the patient should not be receiving systemic immunosuppressive medication, cluster of differentiation 4 (CD4) counts at screening should be \\>200/µl)\n* have a known allergy or hypersensitivity to rabbits\n* have platelet count \\<100,000/mL\n* have had within one month prior to first administration of the study drug in this study a major surgical procedure (e.g. orthopedic, abdominal)\n* have received an investigational drug within 30 days of the first study drug administration, or is expected to receive such drug during participation in this study\n* have a clinically relevant hepatic (AST and/or alanine aminotransferase (ALT) \\>3 times the upper limit of normal) and/or renal impairment (creatinine \\>2 times the upper limit of normal)\n* have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, transient ischemic attacks, deep venous thrombosis or pulmonary embolism) within 2 years prior to first dose of study drug, or current New York Heart Association (NYHA) functional classification score of stage II -IV\n* have an active malignancy (those with non-melanoma skin cancer are allowed)\n* have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome (e.g., a history of non-responsiveness to bypassing products).","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Successfully Treated Mild/Moderate Bleeding Episodes","description":"For the primary efficacy endpoint, successful treatment of a bleeding episode was defined as a combination of the following:\n\n* \"Good\" or \"Excellent\" response noted by the patient\n* Study drug treatment: No further treatment with study drug beyond timepoint for this bleeding episode\n* No other hemostatic treatment needed for this bleeding episode\n* No administration of blood products that would indicate continuation of bleeding beyond timepoint\n* No increase of pain beyond timepoint that could not otherwise be explained","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".849","spread":null},{"groupId":"OG001","value":".932","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported \"Good\" or \"Excellent\" Responses at 12 Hours","description":"Based on Patient-Reported \"Good\" or \"Excellent\" responses as per the below descriptions:\n\nGood: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.\n\nExcellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.857","spread":null},{"groupId":"OG001","value":"0.937","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Assessment of a \"Good\" or \"Excellent\" Response of Mild/Moderate Bleeding Episodes by the Patient","description":"Categories of Response to Treatment are Described as Follows:\n\nNone: No noticeable effect of the treatment on the bleed or worsening of patient's condition. Continuation of treatment with the study drug was needed.\n\nModerate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug. Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.\n\nExcellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.98","spread":null},{"groupId":"OG001","value":"3.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"1.75"},{"groupId":"OG001","value":"1.4","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187.868","spread":"131.7982"},{"groupId":"OG001","value":"252.963","spread":"78.9732"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":25},"commonTop":["Nasopharyngitis","Headache"]}}}